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Abstract
Background: Diabetic hyperglycemia and glomerular hyper filtration play a causative role in the progression of chronic kidney 
disease. Renal glucose handling via Sodium-Glucose Cotransporter (SGLT)-2 is a targetable approach and SGLT-2 inhibitors 
have proven therapeutic benefits in diabetic kidney disease. Usnic Acid (UA) is an active constituent of lichen species and symbi-
otic organism of algae and fungi, which is variously studied in folk medicine. The objective of this study was to demonstrate the 
beneficial effects of UA on glucose homeostasis and renal function in streptozotocin-induced diabetic Sprague-Dawley rats and 
to determine whether UA has an effect on regulation of SGLT that may further aid in glucoregulation and renal function.
Methods: Type 1 diabetes was induced in Sprague-Dawley rats with Streptozotocin (STZ, 60mg/kg) by intraperitoneal route on 
day 0. Diabetic rats were treated with UA (75 mg/kg) from day 15 to 35 via oral gavage. On day 35, urine was collected and Oral 
Glucose Tolerance Test (OGTT) was performed. After OGTT, blood was collected through cardiac puncture and kidneys were 
preserved for biochemical analysis. The results are expressed as mean ± standard error of the mean for n=8 rats per study group. 
The data were subjected to 1-way or 2-way ANOVA with Bonferroni’s multiple comparison post hoc test using Graph Pad Prism 
5 and were considered significant at p≤0.05.
Results: Diabetic rats chronically treated with UA had improved hyperphagia, hyperglycemia and glucose intolerance, glomeru-
lar hyper filtration, and urinary protein excretion (p<0.05). However, UA did not prevent loss of circulating insulin in diabetic 
rats. UA’s blood glucose lowering effect was associated with enhanced diuretic-glucosuric response and decreased protein ex-
pression of renal SGLT-1 (p<0.05). While protein expression of SGLT-2 was partially increased in the diabetic kidney and it was 
not decreased by UA. Metabolic corrections with UA treatment occurred in parallel with reductions in uremia and improvement 
of renal function indices. Additionally, in diabetic rat kidney, UA treatment corrected oxidative changes.
Conclusions: Based on preliminary findings we conclude that chronic treatment of UA may act in an insulin-independent manner 
in lowering of diabetic hyperglycemia and improvement of renal function.
Keywords: Glucosuria; Hyperglycemia; Renal Function; 
Sodium-Glucose Cotransporter; Usnic Acid
Introduction
Diabetic hyperglycemia and its renal and cardiovascular 
complications contribute significantly to mortality and healthcare 
cost [1-4]. Hyperglycemia has been shown to promote glomerular 
hyper filtration [5], a phenomenon in diabetes/obesity that serves 
as an early predictor of chronic kidney diseases [6-8]. The concept 
of glomerular hyper filtration as a targetable mechanism to control 
kidney diseases is very old [9]. Nonetheless, hyper filtration is an 
incompletely and poorly understood process defined as an elevated 
baseline glomerular filtration rate. It may contribute to uremic 
toxicity, oxidative stress, inflammation and hypertension that over 
time results in kidney diseases. Control of hyperglycemia has been 
shown to significantly lower the incidence of kidney diseases. 
Therefore, any approach to lower hyperglycemia or hyper filtration 
will be beneficial.
The importance of renal glucose handling has been 
documented for many years. Complete reabsorption of filtered 
glucose by renal proximal tubule cells via luminal SGLT-2 and 
Citation: Amin RP, Patel SN, Kumar S, Zito WS, Barletta MA (2018) Effects of Usnic Acid on Hyperglycemia and Renal Function in Streptozotocin-Induced Diabetic 
Rats. Arch Nat Med Chem ANMC-119. DOI: 10.29011/ANMC-119. 000019
2 Volume 2018; Issue 02
Arch Nat Med Chem, an open access journal 
ISSN: 2577-0195
SGLT-1 is of greater significance and recently became targetable 
tool in diabetes. SGLT-2 (low affinity and high capacity, 90-97%) 
and SGLT-1 (high affinity and low capacity, 3-10%) transporters are 
located in renal proximal tubule. Active reabsorption of glucose via 
SGLT isoforms is driven by an electrochemical gradient created by 
basolateral Na+-K+-ATPase where Glucose Transporter (GLUT)-2 
facilitates passive transport of glucose back to venous circulation 
in favor of a glucose gradient. When renal glucose reabsorption 
is saturated, extra glucose spills in urine, i.e. glucosuria ensues. 
The intensity of glucosuria depends on glomerular filtration, blood 
glucose and renal transport capacity.
Lichens are symbiotic organisms formed by fungi and 
algae. Usnic Acid (UA) is one of the most extensively studied, 
widely distributed and variously utilized dibenzofuran metabolites 
of lichens. Multiple evidences have shown that lichen species 
containing one or both, the (+) and (-) enantiomers, of UA 
exhibit anti-cancer [10,11] and growth inhibitory actions against 
several microorganisms [12,13] and plant pathogens [14]. While, 
Okuyama, et al. [15] showed analgesic and anti-inflammatory 
properties of lichen components-UA and diffractaic acid in mice, 
Vijayakumar and colleagues [16] showed acute and chronic anti-
inflammatory activity of (+) UA in Wistar rats. Administration of 
UA also has shown anti-ulcerogenic and anti-oxidative effects in 
rats [17]. UA containing lichen species have also been used in the 
treatment of tuberculosis [18] and even in folk medicine [19-21]. 
These effects have not been attributed to UA, yet. On the other 
hand, high dose of UA has been reported to cause oxidative hepatic 
injury [22,23] and uncommon adverse reactions [24-26]. As UA 
have shown anti-inflammatory, and anti-oxidative properties, 
we were interested to evaluate its beneficial effects in diabetes. 
In preliminary results, UA showed inhibition of SGLT in porcine 
derived proximal tubule cell line LLC-PK1 (IC50 = 29 μM). To 
allow further therapeutic applications of UA, the present study 
was focused primarily to demonstrate the beneficial effects of 
UA on glucose homeostasis and renal function in streptozotocin-
induced diabetic Sprague-Dawley rats and to determine whether 
UA has an effect on regulation of SGLT that may further aid in 
glucoregulation and renal function.
Material and Methods
Animal Treatment
Male Sprague-Dawley rats were obtained from Taconic 
Farms, Germantown, NY and were kept in a room maintained 
at a temperature of 23±1°C and in a 12hr light/dark cycle. All 
experimental groups were maintained on laboratory rodent diet 
(LabDiet® 5001, PMI Nutrition International, Brentwood, MO) 
and drinking water ad libitum. Animals were randomly divided 
into four groups (n=8 per group): normal rats treated with 10 mM 
citrate buffer (control, i.p.), pH 4.5; untreated diabetic rats (STZ); 
diabetic rats treated with UA (STZ+UA; 75 mg/kg/day, oral gavage, 
days 15-35, once daily). The dose of UA was selected based on 
earlier reports [15-17,23,27,28]. Experimental type 1 diabetes 
was induced by a single administration of STZ (60 mg/kg, i.p.) 
dissolved in citrate buffer (10 mM, pH 4.5) on day 0. STZ solution 
was freshly prepared each time. After 72 hrs of STZ administration, 
the non-fasting blood glucose concentration was determined in 
all animals on day 0,4,7,10,14,21,28 and 35, via the tail pricking 
method (~1 mm) using a commercially available glucometer 
(TRUE track, Nipro Diagnostics, Fort Lauderdale, FL) that utilizes 
the glucose oxidase method. On day 21,28 and 35, blood glucose 
was monitored at 0,4,8 and 24 hours post UA administration to 
determine its effectiveness in lowering of blood glucose. Animals 
having blood glucose over 300 mg/dL were considered diabetic and 
used for further studies. STZ and UA were purchased from Sigma 
Aldrich, San Diego, CA. All animal procedures were performed 
in accordance with guidelines established by the United States 
Department of Agriculture and were approved by the Institutional 
Animal Care and Use Committee of St. John’s University, NY. 
Changes in body weight was monitored every week throughout 
the study. At the end of study (35 days) urine was collected while 
the animals were kept in metabolic cages to evaluate the effect of 
UA on excretion of glucose and renal function. On Day 35, Oral 
Glucose Tolerance Test (OGTT) was performed on all animals to 
evaluate the effect of UA on glucose intolerance. All overnight 
fasted animals were received oral challenge with glucose solution 
(2g/kg). Blood glucose for OGTT was measured via tail pricking 
method (~1 mm) using a commercially available glucometer 
before (0 min) and after (15,30,45,60,90,120,240 and 480 min) 
glucose challenge. After OGTT, the blood sample was collected 
into EDTA-coated tubes through cardiac puncture under isoflurane 
anesthesia and animals were euthanized. Blood was processed 
for plasma preparation (700g,30 min). The kidneys were excised 
by the freeze clamp technique and stored at -80°C. The kidney 
homogenate (10%w/v) was prepared in Phosphate Buffered Saline 
(PBS), pH 7.4, containing protease and phosphatase inhibitors.
Biochemical Analysis
Plasma insulin content was measured by solid-phase, two-
side, direct sandwich ELISA (Calbiotech Inc., Spring Valley, CA). 
The urinary glucose excretion was measured using colorimetric 
assay kit (Procedure No. 510, Sigma Chemical Co., St. Louis, 
MO) representing a minor modification of the method [29]. 
Renal expression of sodium-glucose cotransporter (SGLT)-1 and 
SGLT-2 was quantified via direct sandwich ELISA (Mybiosource 
Inc., San Diego, CA). Urea Nitrogen (UN) and Creatinine (Cr) in 
plasma and urine were measured using colorimetric kit (Stanbio 
Laboratory, Boerne, TX) to estimate indices of renal function 
such as Glomerular Filtration Rate (eGFR), fractional excretion of 
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urea nitrogen (FEUN (%) = 100X (urine urea/plasma urea)/ (urine 
creatinine/plasma creatinine)), blood urea nitrogen to creatinine 
ratio (BUN-to-Cr) and urine-to-plasma creatinine ratio (UPcr). 
GFR was estimated as described earlier by Pestel [30]. Plasma and 
kidney homogenate samples were deproteinized using phosphoric 
acid and used for measurement of reduced (GSH) and oxidized 
glutathione (GSSG). The concentrations of GSH and GSSG in 
kidney and plasma was measured by a fluorometric method that 
uses o-phthalaldehyde as a fluorescent reagent [31]. Reduced and 
oxidized glutathione values were reported in micromole/mg tissue. 
Activities of catalase (CAT), Glutathione Peroxidase (GPx) and 
Super Oxide Dismutase (SOD) were determined by the methods 
of Aebi [32], Günzler and Flohé [33] and Misra [34], respectively, 
and reported as U/mg protein/min.
Statistical Analysis  
The experimental results are expressed as mean ± S.E.M. 
(standard error of the mean) for n=8 per group. The data were 
subjected to 1-way or 2-way ANOVA with Bonferroni’s multiple 
comparison post hoc test using Graph Pad Prism 5 and were 
considered significant at p≤0.05. 
Results 
Effect of UA on Body Weight, Food Intake, Plasma 
Insulin and Blood Glucose
Control rats showed normal body growth (mean: 290±5 g at 
day 0 to 368±11 g at day 35), while body weight of untreated or 
UA-treated diabetic rats remained statistically unchanged during 
study (Figure 1A). Similarly, type 1 diabetic rats showed significant 
hyperphagic response (STZ: 31.4±2.2-34.2±1.8 vs. control: 
25.3±1.8-24.4±2.1 g/rat/day, days 4-35), which was reduced by UA 
(24.8±1.6-27.7±1.9 g/rat/day; days 4-35) (Figure 1B). Diabetic rats 
also showed typical STZ-induced hypoinsulinemia as compared to 
control rats (STZ: 7.5±0.1 vs. control: 15.4±3.4 mU/L). Treatment 
with UA did not prevent loss of insulin (Figure 1C). In diabetic 
rats, STZ-induced hypoinsulinemia was associated with persistent 
hyperglycemia throughout study period (STZ: 360±16-536±18 
vs. control: 91±2- 121±6 mg/dL) (Figure 1D). On day 21, i.e. 
after one week of treatment, UA was able to control rise in blood 
glucose significantly (301±11, 302±10 and 392±50 mg/dL at 4, 8 
and 24 hour) which remained similar on day 28 (316±16, 333±13 
and 372±37 mg/dL at 4, 8 and 24 hour) and day 35 (300±15, 326±8 
and 369±16 mg/dL at 4, 8 and 24 hour).
Figure 1: Effect on (A) body weight, (B) food consumption, (C) plasma insulin and (D) blood glucose before (days 0-14) and after (day 21, 28 and 
35) treatment with Usnic Acid (UA) in Streptozotocin (STZ)-induced diabetic rats. Results are expressed as mean ± S.E.M. for n=8 per group. The 
results were subjected to 1-way (C) or 2-way (A, B, D) ANOVA with Bonferroni’s multiple comparison post hoc test using Graph Pad Prism 5 and were 
considered significant at p≤0.05; *vs. control, #vs. STZ.
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Effect of UA on Oral Glucose Tolerance Test
Diabetic rats showed significant glucose intolerance, i.e. 
higher blood glucose (554±15-442±18 mg/dL) persisted longer for 
480 minute (Figure 2). Whereas normal control rats showed only 
modest increases in blood glucose (90±3 -174±13 mg/dL) which 
was normalized completely at 90 minute. Glucose intolerance 
in diabetic rats was significantly r-educed with UA treatment 
(325±23-472±24 mg/dL).
Figure 2: Effect of usnic acid on Oral Glucose Tolerance Test (OGTT) in 
Streptozotocin (STZ)-induced diabetic rats. On Day 35, overnight fasted 
animals were administered with UA or vehicle control 15 min before oral 
challenge with glucose solution (2 g/kg). Glucose levels were determined 
at 0,15,30,45,60,90,120,240 and 480 minute after oral glucose challenge. 
Results are expressed as mean ± S.E.M. for n=8 per group. The results 
were subjected to 2-way ANOVA with Bonferroni’s multiple comparison 
post hoc test using Graph Pad Prism 5 and were considered significant at 
p≤0.05; *vs. control, +vs. STZ.
Effect of UA on Diuresis and Indices of Renal Function
In comparison to normal control rats, diabetic rats as 
expected showed significant diuresis (STZ: 68±5 vs. control: 
15±1 mL/day) which was further increased by UA (81±4 mL/day) 
(Figure 3A). Correspondingly, diabetic rats also showed significant 
urinary protein excretion (STZ: 3.7±0.4 vs. control: 1.0±0.1 mg/h) 
which was reduced with UA treatment (2.8±0.3 mg/h) (Figure 
3B). Untreated diabetic rats exhibited glomerular hyper filtration 
as determined by eGFR (STZ: 59.3±6.2 vs. control: 9.7±0.4 µL/
min) which was reduced significantly with UA (41.8±2.8 µL/
min) (Figure 3C). In the same way, index of renal excretory and 
reabsorptive capacity FEUN (STZ: 240±37 vs. control: 105±6 
%) (Figure 3D) and an index of acute kidney injury BUN-to-Cr 
ratio (STZ: 95±10 vs. control: 66±4) (Figure 3E) were markedly 
increased in diabetic rats which were normalized with UA treatment 
(FEUN: 85±6; BUN-to-Cr: 61±6). However, UPcr, an index of distal 
tubular water handling remained statistically unchanged in study 
groups (Figure 3F).
Figure 3: Effects of chronic treatment of usnic acid on (A) urine volume, 
(B) urinary protein excretion, (C) estimated glomerular filtration rate 
(eGFR), (D) fractional excretion of urea nitrogen (FEUN, %), (E) Blood 
Urea Nitrogen-to-Creatinine ratio (BUN-to-Cr) and (F) Urine-to-Plasma 
Creatinine ratio (UPcr) in Streptozotocin (STZ)-induced diabetic rats. 
Results are expressed as mean ± S.E.M. for n=8 per group. The results 
were subjected to 1-way ANOVA with Bonferroni’s multiple comparison 
post hoc test using Graph Pad Prism 5 and were considered significant at 
p≤0.05; *vs. control, #vs. STZ.
Effect of UA on Glucosuria and Renal Expression of 
SGLT-1 and SGLT-2
As expected, normal control rats showed negligible 
glucosuria, i.e. urinary excretion of glucose (1.9±0.2 mg/h) which 
was found significantly elevated in diabetic rats (20.3±2.5 mg/h) 
(Figure 4A). UA treatment increased glucosuric response further 
(32.0±0.8 mg/h) in diabetic rats. However, renal protein expression 
of SGLT-2, a predominant isoform responsible for glucosuric 
response remained statistically unchanged in study animals 
(Figure 4B). On contrary, protein expression of SGLT-1 was found 
increased in diabetes (STZ: 3.49±0.35 vs. control: 2.85±0.26 ng/
mg protein) which was reduced with UA treatment (2.48±0.20 ng/
mg protein) (Figure 4C).
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Figure 4: Effects of chronic treatment of usnic acid on (A) urinary excretion of glucose and renal expression of (B) SGLT-2 and (C) SGLT-1 protein 
in Streptozotocin (STZ)-induced diabetic rats. Results are expressed as mean± S.E.M. for n=8 per group. The results were subjected to 1-way ANOVA 
with Bonferroni’s multiple comparison post hoc test using Graph Pad Prism 5 and were considered significant at p≤0.05; *vs. control, #vs. STZ.
Effect of UA on Indices of Oxidative Stress in Kidney
In general, oxidative stress in untreated diabetic rat kidney was found modestly affected in comparison to normal control rat 
kidney. In diabetic kidney, activity of SOD was found increased (STZ: 6.25±0.89 vs. control: 5.13±0.47 U/mg protein/min) which was 
reduced with UA treatment (4.65±1.23 U/mg protein/min) (Figure 5A). But activity of CAT was found decreased in diabetic kidney 
(STZ: 0.36±0.08 vs. control: 0.53±0.03 U/mg protein/min) and UA treatment prevented decreases in CAT activity (0.53±0.14 U/mg 
protein/min) (Figure 5B). Activity of GPx was found increased in diabetic kidney (STZ: 11.3±1.7 vs. control: 7.4±0.4 U/mg protein/
min) which was normalized with UA treatment (6.6±1.1 U/mg protein/min) (Figure 5C). Of physiological merit, the GSH: GSSG ratio 
in diabetic kidney was decreased as compared to control (STZ: 0.29±0.02 vs. control: 0.33±0.03) which was again prevented with UA 
(0.37±0.04) (Figure 5D).
Figure 5: Effects of chronic treatment of usnic acid on activities of (A) Superoxide Dismutase (SOD), (B) Catalase (CAT), (C) Glutathione Peroxidase 
(GPx) and (D) Reduced Glutathione (GSH)-to-Oxidized Glutathione (GSSG) in kidney of Streptozotocin (STZ)-induced diabetic rats. Results are 
expressed as mean ± S.E.M. for n=8 per group. The results were subjected to 1-way ANOVA with Bonferroni’s multiple comparison post hoc test using 
Graph Pad Prism 5 and were considered significant at p≤0.05; *vs. control, #vs. STZ.
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Discussion
Rats treated with STZ showed typical responses of diabetes 
such as hyperphagia, hypoinsulinemia, reduced weight gain, 
persistent hyperglycemia, severe glucose intolerance and renal 
dysfunction. To the best of our knowledge, this preliminary chronic 
study is the first to demonstrate the beneficial effects of UA in 
STZ-induced rats with hyperglycemia and renal dysfunction. In 
this study the glucose lowering effect of UA was not associated 
with normalization of circulating insulin. This suggests it may have 
a potential role as an insulin-independent co-treatment with insulin 
secretagogues or insulin to lower diabetic hyperglycemia at any 
stage of diabetes. Such an insulin-independent approach possesses 
minimal risk of hypoglycemia with UA treatment. These results 
suggest that UA may have improved glucose metabolism since UA-
treated diabetic rats also exhibited reduced glucose intolerance. 
It is likely that changes in appetite or energy expenditure with 
UA treatment may have occurred over time which contributed to 
changes in blood glucose. Although, further studies are needed to 
clarify such mechanisms.
Diabetic rats as expected showed a glucuretic response. 
Concurrent UA treatment further enhanced this response and 
may have added benefits in reducing extracellular volume and 
circulating glucose load. Results suggest, this benefit may not 
be due to a decreased number of SGLT-2 since renal expression 
of this isoform remained unchanged in study animals. Thus, it is 
likely that UA may either have reduced the activity of SGLT-2 
or modulated the expression and/or activity of GLUT-2. These 
require further detailed investigation. Moreover, SGLT-2 inhibition 
has been shown to unmask SGLT-1 significantly (~40%) [35]. In 
agreement with this notion, untreated diabetic rats showed an 
increase in renal SGLT-1 expression that was reduced significantly 
by UA. So, it is likely that UA’s glucuretic effects were also due 
to a reduced number of renal SGLT-1 isoforms. Vidotti, et al. [36] 
also have reported increased renal cortical expression of SGLT-1 
protein after long term type 1 diabetes which was normalized with 
insulin therapy. In untreated diabetic kidneys, oxidative stress 
seemed to favor formation of hydrogen peroxide as activity of 
SOD was increased while CAT activity was decreased in our study. 
A compensatory detoxification of hydrogen peroxide may have led 
to a decrease in GSH: GSSG and increase in GPx activity. Yet, UA 
normalized such modest enzymic changes which is in agreement 
with past reports [17,20]. Oxidative stress in diabetes has been 
associated with increase in renal threshold of glucosuria and 
facilitated renal reabsorption of glucose via both SGLT isoforms. 
Based on preliminary results, it may be considered that chronic 
treatment of UA may have beneficial glucosuric effects that are 
partially dependent on its ability to mitigate oxidative changes.
While studying renal regulation of blood glucose it is 
important to determine renal function changes. Although glomerular 
hyperfiltration is an early reliable predictor of renal dysfunction, 
significant challenges exist for the field of hyperfiltration. A 
pathological decline in Glomerular Filtration Rate (GFR) might be 
indistinguishable from a ‘beneficial’ resolution of hyperfiltration 
over a short follow up. Moreover, renal function varies considerably 
when diuresis occurs, e.g. during diabetes. Therefore, analysis of 
multiple sensitive and specific indices would satisfactorily predict 
progression of renal function. Appearance of protein in urine as a 
function of glomerular filtration is a very sensitive marker of renal 
function [37]. Diabetic rats treated with UA showed a reduced rate 
of protein excretion which suggests UA may have protected the 
glomerular leakage of protein. Tubular epithelium is a barrier that 
regulates the composition of the glomerular filtrate. Urea Nitrogen 
(UN) and Creatinine (Cr) are filtered through the glomerulus. 
UN is reabsorbed, while Cr is neither secreted nor reabsorbed 
in renal tubules. Thus, Cr clearance does not indicate tubular 
function. Also, glomerular filtration of Cr is one of the factors that 
determines Cr concentration in serum [38]. Conversely, FEUN, a 
function of urea and Cr clearance with glomerular filtration, is a 
sensitive and reliable predictor of renal excretory and reabsorptive 
capacity [39,40]. In diabetic rats, hyperfiltration with an increase 
in FEUN indicates reabsorption uremia. BUN-to-Cr is also used 
in conjunction with FEUN for gross determination of uremic 
abnormalities. Preliminary results suggest that chronic treatment 
with UA normalized reabsorption of urea and may have protected 
kidney against uremic toxicity in diabetic rats. Likewise, urine-to-
plasma creatinine (UPcr) ratio is a measure of urinary concentrating 
ability of distal tubules. Usually, increases in FEUN is associated 
with a decline in UPcr under severe renal damage. In the present 
study, UPcr is partially depressed in untreated and UA-treated 
diabetic rats therefore we speculate that diabetes did not affect 
distal tubules. Additionally, histological analysis would support 
our finding and we do agree that absence of histological result is a 
severe limitation of our study.
Conclusions
Preliminary results of our chronic study show that UA may act 
in an insulin-independent manner to lower diabetic hyperglycemia 
[41] as well as may protect kidney against uremic abnormalities 
[42]. Based on results, it may appear that UA-mediated lowering 
of glucose is not sufficient to meet daily anti-hyperglycemic target, 
but this does not rule out the possible beneficial actions of UA 
in diabetic kidney diseases. Adjunct therapy of UA with insulin 
secretagogues or insulin may provide greater benefits, however 
further studies are needed to confirm the glucoregulatory and 
renoprotective mechanism(s) of UA in diabetes [43].
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